Achaogen (AKAO) Price Target Raised to $31.00 at HC Wainwright
Achaogen (NASDAQ:AKAO) had its price target upped by HC Wainwright from $25.00 to $31.00 in a research report sent to investors on Wednesday, MarketBeat Ratings reports. They currently have a buy rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also weighed in on AKAO. Guggenheim started coverage on Achaogen in a research note on Tuesday, October 24th. They issued a buy rating and a $17.00 target price for the company. Mizuho restated a buy rating and set a $28.00 price target on shares of Achaogen in a report on Monday, October 30th. Stifel Nicolaus reduced their price target on Achaogen from $30.00 to $27.00 and set a buy rating on the stock in a report on Thursday, November 9th. Zacks Investment Research downgraded Achaogen from a hold rating to a sell rating in a report on Tuesday, November 14th. Finally, ValuEngine upgraded Achaogen from a sell rating to a hold rating in a report on Sunday, December 31st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of Buy and an average price target of $26.16.
Shares of Achaogen (AKAO) opened at $10.54 on Wednesday. Achaogen has a 52 week low of $9.83 and a 52 week high of $27.79. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.99 and a current ratio of 6.99.
In other Achaogen news, major shareholder Robert W. Duggan purchased 50,000 shares of Achaogen stock in a transaction that occurred on Friday, January 5th. The shares were bought at an average price of $11.51 per share, for a total transaction of $575,500.00. Following the acquisition, the insider now directly owns 5,617,752 shares in the company, valued at $64,660,325.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Robert W. Duggan purchased 95,012 shares of Achaogen stock in a transaction that occurred on Monday, December 18th. The shares were acquired at an average price of $11.13 per share, for a total transaction of $1,057,483.56. Following the acquisition, the insider now owns 5,602,752 shares in the company, valued at $62,358,629.76. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 160,012 shares of company stock worth $1,796,334. 8.36% of the stock is owned by company insiders.
Hedge funds have recently bought and sold shares of the business. Legal & General Group Plc purchased a new position in shares of Achaogen during the 2nd quarter worth approximately $168,000. Ardsley Advisory Partners purchased a new position in shares of Achaogen during the 2nd quarter worth approximately $217,000. JPMorgan Chase & Co. grew its holdings in shares of Achaogen by 691.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 11,077 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 9,677 shares during the period. California Public Employees Retirement System purchased a new position in shares of Achaogen during the 2nd quarter worth approximately $243,000. Finally, Voya Investment Management LLC purchased a new position in shares of Achaogen during the 2nd quarter worth approximately $295,000. Hedge funds and other institutional investors own 85.84% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/02/10/achaogen-akao-price-target-raised-to-31-00-at-hc-wainwright.html.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.